Benzinga | Oct 7, 2021 07:27AM EDT

Amgen, Neumora Collaborate On Precision Therapies for Brain Diseases

* Amgen Inc (NASDAQ:AMGN) and Neumora Therapeutics Inc have announced a strategic collaboration to advance neuroscience discovery, development, and commercialization.

* The companies will collaborate on programs by applying Neumora's proprietary precision neuroscience platform to insights generated by Amgen's deCODE genetics and human data research capabilities.

* Deal terms for the collaboration were not disclosed.

* In addition, Neumora has received a $100 million equity investment from Amgen and acquired exclusive global rights to Amgen programs targeting casein kinase 1 delta and glucocerebrosidase for neurodegenerative diseases.

* Related: Amgen's Lumakras Combo Therapy Shows Improved Response Rate In Colorectal Cancer.

* Price Action: AMGN stock closed 0.89% lower at $209.98 on Wednesday.